Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 China Information Technology, Inc. (the "Company" ... integrated cloud-based platform, exchange, and big data solutions in ... Company launched its mobile app for Healthcare One Pass, ... on mobile devices. The Company jointly hosted the launch ... Bureau and Shenzhen News Net.   The mobile ...
(Date:7/5/2015)... July 6, 2015 Nihon University is ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up ... 2015 in Tokyo, Japan . ... applied research will present their achievements and future ... new industry produced with 8K technology. ...
(Date:7/4/2015)... , Spanje, July 4, 2015 ... harsmicrosferen aan eerstelijns chemotherapie voor patiënten met ... (mCRC) verlengt de progressievrije overleving in dat ... gemetastaseerde colorectale kanker (mCRC) die alleen binnen ... gezien in progressievrije overleving (PFS) in de ...
Breaking Medicine Technology:CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
... 2010 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. ... "Company"), which is engaged in the research, development, ... cosmetic products in the People,s Republic of China ... (the "NYSE Amex" or "Exchange") has accepted the ...
Cached Medicine Technology:Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing 2NYSE Amex Accepts China Shenghuo's Compliance Plan for Continued Listing 3
(Date:7/6/2015)... News, VA (PRWEB) , ... July 06, 2015 ... ... today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® ... Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and a generous grant ... Music & Memory Certification for hospice patients and adult day center participants. , The ... to patients but also to their families and volunteers. Music & Memory is a ...
(Date:7/5/2015)... MN (PRWEB) , ... July 06, 2015 , ... ... the ancillary benefits market, is excited to announce the next generation of PrimeStar ... and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women's Excellence in Wellness, powered by ... These classes are geared towards families that want their children to stay active as ... The fitness class will take place TUESDAYS at 4:30pm. Questions? Call 248-601-6683. Women’s ...
(Date:7/5/2015)... , ... July 05, 2015 , ... Women’s Excellence ... college) at their Lake Orion location. The special consists of 2 months of unlimited ... Wellness, powered by Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
Breaking Medicine News(10 mins):Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... Today the Global AIDS,Alliance Fund responded to the plan ... Dr. Paul Zeitz, Executive Director of the Global ... other experts will discuss the,issue further on a conference ... thrilled to see Senator Clinton,s plan of action on ...
... high-tech identification system,developed in Japan will improve accuracy ... victims of mass disasters, according to a study,presented ... Society of North,America (RSNA)., "Families waiting to ... for the identification process to resolve," said Eiko ...
... dies. It is still not possible to restore the scar ... stem cell researchers attempt to make new heart muscle cells ... Center, however, was able to prove the concept of using ... heart: this cell therapy ensured that less tissue died and ...
... SURGEONS, GREATER ACCESS TO PATIENT DATA AND IMAGES IN THE ... ... ALISO VIEJO, Calif., Nov. 27 Global Care Quest, Inc.,(GCQ), an innovator ... leader in minimally invasive,endoscopic technologies and operating room integration, and GCQ have,expanded ...
... LOS ANGELES, Calif., Nov. 27 Los Angeles, ... Therapy, are joining,forces to create a unique partnership ... cosmetic services., (Photo: http://www.newscom.com/cgi-bin/prnh/20071127/CLTU058 ), ... Laser Hair Therapy, a,safe procedure that assists in ...
... to ... Pharmacopeia, PRINCETON, ... the discovery and development of novel,small molecule therapeutics, announced today that ... with GlaxoSmithKline (NYSE:,GSK), through its collaboration with the Center of Excellence ...
Cached Medicine News:Health News:Senator Clinton's Plan 'The Kind of Leadership We Need on AIDS' 2Health News:New Automated System IDs Victims of Mass Disasters in Minutes 2Health News:New Automated System IDs Victims of Mass Disasters in Minutes 3Health News:KARL STORZ and Global Care Quest Announce Extension of Marketing Agreement 2Health News:KARL STORZ and Global Care Quest Announce Extension of Marketing Agreement 3Health News:Low-level Laser Therapy Clinics' Partnership Targets Helping People Nationwide 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 2Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 3Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 4Health News:Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds 5
Microforceps: Claes ILM Forceps...
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps with "nail-like" end-gripping platforms; for precise grasping and improved visualization of thin membranes in the macular region....
Microforceps : Eckardt Endgripping Forceps...
Medicine Products: